



FOR IMMEDIATE RELEASE

Contact: Andy Lee - Vincere Biosciences

Phone: 857-245-9492

Email: info@VincereBio.com

Vincere Biosciences Receives Funding from NIH, National Institute of Aging (NIA)

Cambridge, MA, USA - June 2022: Vincere Biosciences, the Cambridge-based biotech company developing therapeutics to stop the progression of Parkinson's disease, is now expanding into cardiac and longevity indications with \$300,000 of new funding from the National Institute of Aging (NIA).

Vincere's lead assets increase recycling of damaged mitochondria through a process called mitophagy. Vincere CEO **Dr. Spring Behrouz** explains **"Our mission is to conquer age-related decline. Damaged mitochondria are major contributors to aging and multiple diseases of aging. We are thrilled that NIA reviewers agree that our small molecules, which clear damaged mitochondria, have the potential to reduce heart aging."**

Dr. Daniel R. Goldstein, MD of the University of Michigan's School of Medicine and Director of Michigan Biology of Cardiovascular Aging (M-BoCA), writes, **"This is a project with high potential impact"**, noting the current **"unmet needs in developing disease modifying treatments for heart failure."**

With this funding, Vincere is growing its team in the Boston area with additional scientists to perform these experiments and further solidify their platform for boosting mitophagy and mitochondrial health.

Heart failure affects over 6 million adults in the US costing the nation over \$30 billion, presenting a large unmet need and opening a new market for growth with strong interest from potential pharmaceutical partners. For more information reach out to info@vincerebio.com.

About Vincere Biosciences Inc: Vincere Biosciences was founded in 2018 and develops therapeutics for neurodegenerative disease empowered by a unique suite of computational tools coupled with traditional biology and drug discovery. Vincere is Latin for “To win,” a constant reminder of our mission to win the fight against age-related decline.

Visit <http://www.vincerebio.com> for more information about Vincere Biosciences.

About The National Institutes of Health Small Business Programs: The National Institutes of Health (NIH) small business program is a congressionally-mandated set-aside program to encourage research and development leading to commercialization. The program, as established by law, is intended to stimulate a partnership of ideas and technologies in the private sector and strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs.

The NIA SBIR/STTR program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public benefit. NIA is increasingly tracking the progress of its funded small business concerns and the products they develop. Funding priority will be given to those small business concerns that show not only their ability to develop products but their growth as a small business concern towards independence from the SBIR/STTR program.